Trabectedin + Dexamethasone
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Endometrial Neoplasms
Conditions
Endometrial Neoplasms, Uterine Neoplasms, Genital Neoplasms, Female Urogenital Neoplasms
Trial Timeline
Jul 1, 2002 → Jul 1, 2004
NCT ID
NCT00050440About Trabectedin + Dexamethasone
Trabectedin + Dexamethasone is a phase 2 stage product being developed by Johnson & Johnson for Endometrial Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT00050440. Target conditions include Endometrial Neoplasms, Uterine Neoplasms, Genital Neoplasms, Female Urogenital Neoplasms.
What happened to similar drugs?
0 of 20 similar drugs in Endometrial Neoplasms were approved
Approved (0) Terminated (0) Active (20)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00579501 | Phase 2 | Completed |
| NCT00050414 | Phase 2 | Completed |
| NCT00050440 | Phase 2 | Completed |
Competing Products
20 competing products in Endometrial Neoplasms